Backed by Science: Celebrating Our 9th Peer-Reviewed Study

When we say ‘CELLIANT® is backed by science’ that’s more than a good headline, it reflects our commitment to transparency, extensive testing and, ultimately, proving that CELLIANT is effective.

Every peer-reviewed study is a cause to celebrate as it’s one more significant step on our journey to bring wellness through infrared energy. So it’s with great excitement that we announce our 9th peer-reviewed study, a randomized double-blind placebo-controlled trial with 68 people, that was recently published in the Research Journal of Textile and Apparel.

This study shows that CELLIANT increases grip strength when used in armbands on people with chronic wrist or elbow pain caused by carpal tunnel syndrome, epicondylitis (commonly known as tennis elbow, golfer’s elbow or baseball elbow) or arthritis. The study also notes that since CELLIANT armbands are easy to wear, cost-effective and have not been shown to produce any adverse effects, there should not be any barrier to widespread use.

Here’s a quick breakdown of the details of the study and we invite you to check it out in its entirety in the Research Journal of Textile and Apparel.

How was the study conducted?

68 subjects, both males and females aged 21 or older, had a six-month history of chronic wrist or elbow pain. They wore an armband (35 with CELLIANT and 33 with the placebo fabric) on the affected wrist or elbow for at least 12 hours per day for 14 days. Grip strength was measured by a dynamometer before and after the two-week study.

What were the results?

The mean grip strength percentage increased over two weeks by 7.8% for the placebo group and 16.8% for the CELLIANT group. No adverse effects were observed.

Who conducted and approved the study?

The protocol for the study was approved by the IRB (Institutional Review Board) of Southern California Institute for Research and Education and registered at

Ian L. Gordon of Veterans Affairs Long Beach Healthcare System in Long Beach, California, participated in the conception and design of the study, carried out subject recruitment and data collection and took part in the statistical analysis.

Seth Casden, Hologenix Co-Founder and CEO, participated in the conception and design of the study, provided materials and funding, and helped draft the manuscript.

Michael R. Hamblin of the Laser Research Center, University of Johannesburg – Doornfontein Campus, Doornfontein, South Africa, wrote the manuscript and critically reviewed the data. Hamblin, who serves on the Hologenix Science Advisory Board and is a world-renowned expert on infrared and light therapy, was supported by the U.S. National Institutes of Health (NIH) grants. All authors read and approved the final manuscript.